Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 0.61 |
| ▸ | PIK3CD | O00329 | 14/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 14/20 | 0.53 |
| ▸ | PIK3CB | P42338 | 13/20 | 0.53 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.51 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.47 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.47 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.47 |
| ▸ | PI4KA | P42356 | 1/20 | 0.47 |
| ▸ | PRKDC | P78527 | 1/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11938408 | 0.88 | PIK3CA (0.51) | PIK3CAPIK3CDPIK3CGPIK3CBPIK3R1 | |
| SCHEMBL944398 | 0.83 | PIK3CA (0.61) | PIK3CAPIK3CDPIK3CGPIK3CBPIK3R1 | |
| SCHEMBL12943751 | 0.82 | PIK3CA (0.60) | PIK3CAPIK3CDPIK3CGPIK3CBPIK3R1 | |
| SCHEMBL13782176 | 0.81 | PIK3CA (0.82) | PIK3CAPIK3CDPIK3CGPIK3CB | |
| SCHEMBL924512 | 0.80 | PIK3CG (0.61) | PIK3CAPIK3CDPIK3CGPIK3CBPIK3R1 | |
| SCHEMBL12943436 | 0.79 | PIK3CA (0.70) | PIK3CAPIK3CDPIK3CGPIK3CBPIK3R1 | |
| SCHEMBL2703529 | 0.79 | PIK3CA (0.54) | PIK3CAPIK3CDPIK3CGPIK3CBPI4KB | |
| SCHEMBL11938366 | 0.79 | PIK3CA (0.79) | PIK3CAPIK3CDPIK3CGPIK3CBPIK3R1 | |
| SCHEMBL12961439 | 0.79 | PIK3CA (0.69) | PIK3CAPIK3CDPIK3CGPIK3CBPIK3R1 | |
| SCHEMBL12943534 | 0.78 | PIK3CA (0.63) | PIK3CAPIK3CDPIK3CGPIK3CBPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2448935-B1 | SUBSTITUTED 2-CARBOXAMIDE CYCLOAMINO UREAS | NOVARTIS AG (CH) | 2015-06-24 | — | — | EP | disclosed |
| EP-2448935-B1 | SUBSTITUTED 2-CARBOXAMIDE CYCLOAMINO UREAS | NOVARTIS AG (CH) | 2015-06-24 | — | — | EP | disclosed |
| US-8940771-B2 | Organic compounds | NOVARTIS AG (CH) | 2015-01-27 | — | — | US | disclosed |
| EP-2240475-B1 | THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-09-25 | — | — | EP | disclosed |
| US-8293753-B2 | Substituted 2-carboxamide cycloamino ureas | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-8293753-B2 | Substituted 2-carboxamide cycloamino ureas | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| CN-102471332-A | Substituted 2-carboxamide cycloaminoureas | NOVARTIS AG | 2012-05-23 | — | — | CN | disclosed |
| EP-2448935-A1 | SUBSTITUTED 2-CARBOXAMIDE CYCLOAMINO UREAS | Novartis AG (CH) | 2012-05-09 | — | — | EP | disclosed |
| CN-101952282-A | Thiazole derivatives as PI 3 kinase inhibitors | NOVARTIS AG | 2011-01-19 | — | — | CN | disclosed |
| US-20110003818-A1 | Substituted 2-Carboxamide Cycloamino Ureas | NOVARTIS AG (CH) | 2011-01-06 | — | — | US | disclosed |
| US-20110003818-A1 | Substituted 2-Carboxamide Cycloamino Ureas | NOVARTIS AG (CH) | 2011-01-06 | — | — | US | disclosed |
| WO-2011000905-A1 | SUBSTITUTED 2-CARBOXAMIDE CYCLOAMINO UREAS | NOVARTIS AG (CH) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011000905-A1 | SUBSTITUTED 2-CARBOXAMIDE CYCLOAMINO UREAS | NOVARTIS AG (CH) | 2011-01-06 | — | — | WO | disclosed |
| EP-2240475-A1 | THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS | Novartis AG (CH) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009080694-A1 | THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163469-A1 | Organic Compounds | NOVARTIS AG | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003818-A1 | Substituted 2-Carboxamide Cycloamino Ureas | UCK2, ULK3, ULK2 | PIK3CA 5/4885PIK3CD 9/4885PIK3CG 39/4885 |
| US-20090163469-A1 | Organic Compounds | PIK3C3, PIK3CA, PIK3CD | PIK3CA 2/4885PIK3CD 3/4885PIK3CG 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.